Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 5/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.35 |
| ▸ | S100A4 | P26447 | 2/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6723197 | 0.92 | MALT1 (0.42) | KMOPTGS2PTGS1FEN1MALT1 | |
| SCHEMBL6729798 | 0.91 | KCNA5 (0.41) | KMOPTGS2PTGS1KCNA5KCNN4 | |
| SCHEMBL6718600 | 0.89 | GLO1 (0.42) | KMOPTGS2PTGS1FEN1MALT1 | |
| SCHEMBL6722680 | 0.88 | PTGS2 (0.39) | KMOPTGS2PTGS1FEN1ALOX5AP | |
| SCHEMBL6722847 | 0.87 | KMO (0.45) | KMOPTGS2PTGS1FEN1MALT1 | |
| SCHEMBL6721604 | 0.86 | PTGS2 (0.51) | KMOPTGS2PTGS1FEN1MALT1 | |
| SCHEMBL6726098 | 0.86 | PTGS2 (0.42) | KMOPTGS2PTGS1FEN1ALOX5AP | |
| SCHEMBL6721925 | 0.86 | CDC25B (0.38) | KMOPTGS2PTGS1FEN1ALOX5AP | |
| SCHEMBL6721436 | 0.86 | PTGS2 (0.40) | KMOPTGS2PTGS1FEN1ALOX5AP | |
| SCHEMBL6722643 | 0.85 | PTGS2 (0.41) | KMOPTGS2PTGS1FEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | KMO 675/4885PTGS2 5/4885PTGS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.